Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells Targeting CD33 and CLL1 in Patients With Acute Myeloid Leukemia

NCT05215015 is registered in ClinicalTrials.gov with Wuxi People's Hospital as lead sponsor.

NCT NCT05215015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Conjugated Antibody Redirecting Natural Killer (CAR-NK) Cells Targeting CD33 and CLL1 in Patients With Acute Myeloid Leukemia
Lead sponsor
Wuxi People's Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
November 30, 2020
Completion date
November 30, 2022
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia